Anastrozole has been tested for reducing estrogens, including estradiol, in men.  Excess estradiol in men can cause benign prostatic hyperplasia , gynecomastia , and symptoms of hypogonadism . It can also contribute to increased risk of stroke, heart attack, chronic inflammation, prostate enlargement and prostate cancer.  Some athletes and body builders use anastrozole as part of their steroid cycle to reduce and prevent symptoms of excess estrogen-- gynecomastia , emotional lability and water retention.  Study data suggest dosages of mg to 1 mg a day reduce serum estradiol by approximately 50% in men, which differs in postmenopausal women. 
(B) (1) Every licensed health professional authorized to prescribe drugs shall keep a record of all controlled substances received and a record of all controlled substances administered, dispensed, or used other than by prescription. Every other person, except a pharmacist or a manufacturer, wholesaler, or other person licensed under section of the Revised Code, who is authorized to purchase and use controlled substances shall keep a record of all controlled substances purchased and used other than by prescription. The records shall be kept in accordance with division (C)(1) of this section.
Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women.